Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well...whatever it is, I'm holding for the long-term. I have done well in the OTC this last month, I can be patient here.
WTF is this? market makers driving prices down so they can acquire cheap shares?
Got a starter here, looks interesting RSPI
Looking good today $$rspi
No prob, I would’ve bought some of those if I could.
thanx for bringing that to my attention. bought 30k more there. RSPI
Looked decent for while yesterday, then I think someone panic sold. I'm holding as I believe interest will increase here.
Looked decent for while yesterday, then I think someone panic sold. I'm holding as I believe interest will increase here.
yea seems RSPI is set to explode
There has been strength here for a couple of weeks. Someone wants this stock.
P.S. I have emailed Jeff Margolis several times over the past year, and I always get a prompt reply back.
These shares are about to become very thin , moon it
Second that motion, diamond hands here in RSPI
Holding my $RSPI ! Market Cap crazy low!
guys let me be the 1st one to say...THIS WILL BE A NICE NEXT 2 WEEKS FOR US! RSPI
.15 - .20 with ease imo....no idea what’s going on with company, but weren’t there some clinical trials occurring
im expecting .20. RSPI
$1 in sight? ;) it’s possible
WSB on Reddit ..... do u buy and hold , diamond hands or paper hands... WSBs is coming here soon
i dont know what youre talking about
Diamond hands , come on man !!
what does that mean? driving up a mountain? smoking ganja? singing high notes? explain
How high you going
can you repeat that in correct English next time?
Are we committed diamond hands here and what size positions do you own, me ? 510k on way to million but under .10 so will support up to .10 , this next 500 k will come over time for support
looks like 47mil!
What is the real float right now after R/S taking everything into account
hey food! looks like of the 99% you already lost, yull be making about 10% back IMO. cool huh? RSPI
yea im thinking .15
yea. too bad food4thought won't be here for this 500% to 1000% spike thats going to happen. RSPI
Yup, I agree Epic run on the way!! Awesome News $Rspi
that 8k is AWESOME@ An infusion of about $100k in cash w convertible notes not due til nov2021! and only at a 10% discount? talk about a good deal f9r us! RSPI
nice. infusion of cash with restricted shares. GREAT RSPI
i still dont feel sorry for you. youve done that for yourself...feeling sorry for yourself.
I should have known.
You’re not even in the same area code pal. But keep flipping pennies. Lol. I lost more in this company a decade ago than you have in your entire investment account. Enjoy counting your pennies. Cheers. Lol. Blocked.
https://investorshub.advfn.com/uimage/uploads/2021/2/19/bybkmrspi.PNG
This is just 1 of my 5 accts. dont think ill be going broke that soon. do you? hahahaha you probably have like $200 in your acct now.
Please tell me all you know about the company that you’re promoting. You don’t know shit so you resort to insulting someone that does. Congrats. You’re a professional dipshit that will be left broke soon. I’m done with youre worthless banter. Real cute. Yeah you’re funny.
at least im getting a meal. youre just getting the garbage can out back. sucks to be YOU RSPI
You’re a dipshit. Clearly. Enjoy your pennies. Work towards that happy meal you’ve always wanted.
hahaha. did you just say you INVEST in OTC companies? INVEST? really? interesting. so you just hold hold hold hold hold OTC companies forever and ever and ever? I have to admit. you provided a nice comic relief to our cute little ihub page! thanx
Yeah. The chart matters for a two cent flip. The ship went down a decade ago. Get over yourself. Technicals have nothing to do with the future of the company and it’s success. That’s all I was referring to. Play the charts all you want, that doesn’t mean the company is doing great with an international presence. That’s the joke of it all, not the fact that I’m telling you the company is a piece of shit with no future prospects in their pipeline.
yea youre definitely THE GO DOWN WITH THE SHIP type. lol. you probably dont even know what a chart is. i dont feel sorry for you either. ill let you do that for yourself.
And I’d love to bask in your knowledge of this company that you’re touting. This a public forum used most by fools. Clearly your one of them that doesn’t have a clue as to what you’re investing in other than that someone told you it’s going to the moon. Enjoy the penny flipping rabbit hole. I’m sure you’ll many millions. Lol.
When it’s worthless...what’s the point in selling. That’s why I own it, not because I believe in the company you fool. You don’t read between the lines well do you.
I know the history of this company far more than you ever will. Apparently you don’t take insight very well, but hey, enjoy your investment. I’ll be rooting for you.
ok i get it. youre a
retard missing a chromosome talking negatively about the very stock you own. you must hate money w dyslexia.
Followers
|
352
|
Posters
|
|
Posts (Today)
|
54
|
Posts (Total)
|
49347
|
Created
|
12/30/04
|
Type
|
Free
|
Moderators oldstocks DTGoody powerbattles fly_fisherman archilles jacksonjohn |
RespireRx Pharmaceuticals Inc. and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder (“ADHD”), recovery from spinal cord injury (“SCI”), certain neurological orphan diseases and obstructive sleep apnea (“OSA”). The RespireRx Group is developing a pipeline of new and repurposed drug products based on our broad patent portfolios for two drug platforms: (i) neuromodulators, which include GABAkines and AMPAkines, proprietary chemical entities that positively modulate (positive allosteric modulators or “PAMs”) GABAA receptors and AMPA-type glutamate receptors, respectively, and (ii) pharmaceutical cannabinoids, which include dronabinol, a synthetic compound that acts upon the nervous system’s endogenous cannabinoid receptors and
The RespireRx Group holds exclusive licenses and owns patents and patent applications or rights thereto for certain families of chemical compounds that claim the chemical structures and their uses in the treatment of a variety of disorders, as well as claims for novel uses of known drugs.
EndeavourRx: Neuromodulators
GABAkines. Under a License Agreement with the University of Wisconsin-Milwaukee Research Foundation, Inc. (“UWMRF”) and on behalf of its EndeavourRx business unit, RespireRx has licensed rights to certain selectively acting GABAkines because of their ability to selectively amplify inhibitory neurotransmission at a highly specific subset of GABAA receptors, thus producing a unique efficacy profile with reduced side effects. Preclinical studies have documented their efficacy in a broad array of animal models of interrelated neurological and psychiatric disorders including epilepsy, pain, anxiety, and depression in the absence of or with greatly reduced propensity to produce sedation, motor-impairment, tolerance, dependence and abuse. EndeavourRx currently is focusing on developing KRM-II-81 for the treatment of epilepsy and pain.
KRM-II-81 has displayed a high degree of anti-convulsant activity in a broad range of preclinical studies, including in treatment resistant and pharmaco-resistant models. Not only was KRM-II-81 highly effective in these models, but pharmaco-resistance or tolerance did not develop to its anti-convulsant properties. These latter results are particularly important because pharmaco-resistance occurs when medications that once controlled seizures lose efficacy as a result of chronic use and it is a principal reason some epileptic patients require brain surgery to control their seizures. In support of its potential clinical efficacy, translational studies have demonstrated the ability of KRM-II-81 to dramatically reduce epileptiform electrical activity when administered in situ to brain slices excised from treatment resistant epileptic patients undergoing surgery.
In addition, KRM-II-81 has displayed a high degree of analgesic activity in a broad range of preclinical studies. In intact animal models of pain, the analgesic efficacy of KRM-II-81 was comparable to or greater than commonly used analgesics. At the same time, KRM-II-81 did not display side effects such as sedation and motor impairment, but even more importantly, it did not produce tolerance, dependence, respiratory depression or behavioral changes indicative of abuse liability, which are produced by opioid narcotics and are at the heart of the opioid epidemic.
AMPAkines. Through an extensive translational research effort from the cellular level through Phase 2 clinical trials, RespireRx has developed a family of novel, low impact AMPAkines, including CX717, CX1739 and CX1942 that may have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and certain orphan indications. Our lead clinical compounds, CX717 and CX1739, have successfully completed multiple Phase 1 safety trials. Both compounds have also completed Phase 2 proof of concept trials demonstrating target engagement, by antagonizing the ability of opioids to induce respiratory depression.
AMPAkines have demonstrated positive activity in animal models of ADHD, results that have been extended translationally into statistically significant improvement of symptoms observed in a Phase 2 human clinical trial of CX717 in adult patients with ADHD. Statistically significant therapeutic effects were observed within one week. We believe AMPAkines may represent a novel, non-stimulant treatment for ADHD with a more rapid onset of action than alternative non-stimulants, such as Straterra® (atomoxetine), and without the drawbacks of amphetamine-type stimulants.
In a series of important studies funded by grants from the National Institutes of Health and published in a number of peer reviewed articles, Dr. David Fuller (University of Florida), a long-time RespireRx collaborator, has demonstrated the ability of CX1739 and CX717, RespireRx’s lead AMPAkines, to improve motor nerve activity and muscle function in a number of animal models of spinal cord injury (SCI).
FORM TYPE | RECEIVED | PERIOD END DATE | REPORT |
---|---|---|---|
8-K | 02/02/2024 | 01/30/2024 | PDFRTFHTMLXLS |
8-K | 01/22/2024 | 01/18/2024 | PDFRTFHTMLXLS |
8-K | 12/11/2023 | 12/06/2023 | PDFRTFHTMLXLS |
10-Q | 11/17/2023 | 09/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 11/14/2023 | 09/30/2023 | PDFRTFHTML |
8-K | 10/12/2023 | 10/09/2023 | PDFRTFHTMLXLS |
8-K | 10/02/2023 | 09/26/2023 | PDFRTFHTMLXLS |
10-Q | 08/21/2023 | 06/30/2023 | PDFRTFHTMLXLS |
NT 10-Q | 08/14/2023 | 06/30/2023 | PDFRTFHTML |
8-K | 08/09/2023 | 08/03/2023 | PDFRTFHTMLXLS |
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions.
There is no express or implied solicitation to buy or sell securities.
The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned.
Readers are advised to conduct their own due diligence prior to considering buying or selling any stock.
All information should be considered for information purposes only.
No stock exchange has approved or disapproved of the information here
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |